ClinicalTrials.gg
CompletedNCT02183532Updated Jul 8, 2014

Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers

A Phase 1 interventional study of BI 1356 BS and BI 1356 BS in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Study to investigate the pharmacokinetics of BI 1356 after single and multiple oral doses of 5 mg in Chinese healthy subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male and female Chinese healthy volunteers who meet the criteria below:

  • Persons without clinically remarkable findings or clinically evident complications based on their concurrent illness, past medical history, physical examination, vital signs (blood pressure, pulse rate, and body temperature), 12-lead (ECG), and laboratory test results
  • Age ≥18 and Age ≤45 years
  • Body weight ≥50 kg with ≥19 and BMI ≤24 kg/m2 (Body Mass Index)
  • Signed and dated written prior to admission to the study in accordance with Good clinical Practice (GCP) and the local legislation

Exclusion criteria

Exclusion Criteria:

  • Persons who deviate from the norm, and who show clinical findings (Blood pressure (BP), Heart rate (HR), and ) on consultation
  • Persons with any complications
  • Persons with gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immune, or hormonal disorders
  • Persons with central nervous system disorders (e.g., epilepsy), mental disorders, or neurological disorders
  • Persons with a history of significant orthostatic hypotension, syncopal attacks, or blackouts
  • Persons with chronic infection or severe acute infection
  • Persons with a history of severe allergy/ (including allergies to drugs or inactive ingredients)
  • Persons who will have received a drug with a long half-life (more than 24 hours) within the month before treatment in this study, within a period 10 times longer than the half-life of each drug, or during the study
  • Persons who will have received a drug that may theoretically affect the study results based on the information obtained at the time of preparation of the protocol, within the 10 days before treatment or during the study (e.g inhibitors or inducers of Pgp or CYP 3A4)
  • Persons who will have participated in another trial of an drug within the 4 months before treatment or during the study
  • Smokers (who smoke more than 10 cigarettes, or 3 cigars, or 3 pipes per day)
  • Persons who cannot abstain from smoking throughout the study
  • Persons who undoubtedly abuse alcohol
  • Persons who abuse drugs
  • Persons who donate blood of 100 mL or more within the 4 weeks before treatment
  • Persons who perform rigorous exercise (within the week before treatment or during the study)
  • Persons with any laboratory test result outside the reference range and for whom the result is considered a clinically significant change
  • Persons who cannot obey the dieting rules of the study centre
  • Persons with any ECG value outside the reference range and who are of clinical importance. Examples include, but are not limited to, QRS interval >120 ms.
  • Pre-menopausal women (last menstruation \<1 year prior to the date of ) who:

    • are nursing or pregnant
    • or are of and are not practicing an acceptable method of , or do not plan to continue using this method throughout the study and do not agree to periodic pregnancy testing during their participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner. No exception will be made.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    BI 1356 BS

    Drug: BI 1356 BS

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state)

    Time frame: up to day 19

  2. AUCτ (Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to day 19

Secondary outcomes

  1. Cmax (Maximum measured concentration of the analyte in plasma) at different time points after single and multiple doses

    Time frame: up to day 19

  2. tmax (Time from dosing to maximum measured concentration) at different time points after single and multiple doses

    Time frame: up to day 19

  3. AUC0-infinity (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration)

    Time frame: up to day 7

  4. AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of last quantifiable analyte plasma concentration after single dose administration)

    Time frame: up to day 7

  5. AUC0-24 (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 hours after single dose administration)

    Time frame: up to 24 h after single dose administration

  6. AUC0-72 (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours after single dose administration)

    Time frame: up to 72 h after single dose administration

  7. λz (Terminal rate constant in plasma) at different time points after single and multiple doses

    Time frame: up to day 19

  8. t1/2 (Terminal half-life of the analyte in plasma) at different time points after single and multiple doses

    Time frame: up to day 19

  9. MRTpo (Mean residence time of the analyte in the body) at different time points after single and multiple doses

    Time frame: up to day 19

  10. CL/F (Apparent clearance of the analyte in plasma after extravascular administration) at different time points after single and multiple doses

    Time frame: up to day 19

  11. Vz/F (Apparent volume of distribution during the terminal phase λz following extravascular administration) at different time points after single and multiple doses

    Time frame: up to day 19

  12. Aet1-t2 (Amount of analyte that is eliminated in urine from time point t1 to time point t2) at different time points after single and multiple doses

    Time frame: up to 168 h after first dose and up to 24 h after last dose

  13. fet1-t2 (Fraction of analyte eliminated in urine from time point t1 to time point t2) at different time points after single and multiple doses

    Time frame: up to 168 h after first dose and up to 24 h after last dose

  14. Cmin,ss (Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) for multiple doses

    Time frame: up to 144 h after last dose

  15. Cavg,ss (Average concentration of the analyte in plasma at steady state)

    Time frame: up to 144 h after last dose

  16. AUCτ,ss (Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 144 h after last dose

  17. CLRt1-t2,ss (Renal clearance of the analyte at steady state from time point t1 to time point t2)

    Time frame: up to 144 h after last dose

  18. Cpre (Predose concentration of the analyte in plasma) at different time points

    Time frame: up to 120 h after first of multiple doses

  19. PTF (Peak-Trough Fluctuation)

    Time frame: up to 120 h after first of multiple doses

  20. RA,Cmax (Accumulation ratio of the analyte in plasma after multiple dose administration over a uniform dosing interval τ) based on Cmax

    Time frame: up to day 19

  21. RA,AUC (Accumulation ratio of the analyte in plasma after multiple dose administration over a uniform dosing interval τ) based on AUCτ

    Time frame: up to day 19

  22. Number of patients with adverse events

    Time frame: up to 28 days

  23. Number of patients with abnormal findings in physical examination

    Time frame: up to 25 days

  24. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to 25 days

  25. Number of patients with clinically significant changes in Vital signs (blood pressure [BP], pulse rate [PR])

    Time frame: up to 25 days

  26. Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)

    Time frame: up to 25 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009 and a primary completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Jul 2009
Primary completionActual
Jul 2009
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183532
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jul 2009
Primary completion
Jul 2009
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion